IN202321021121A - - Google Patents

Download PDF

Info

Publication number
IN202321021121A
IN202321021121A IN202321021121A IN202321021121A IN202321021121A IN 202321021121 A IN202321021121 A IN 202321021121A IN 202321021121 A IN202321021121 A IN 202321021121A IN 202321021121 A IN202321021121 A IN 202321021121A IN 202321021121 A IN202321021121 A IN 202321021121A
Authority
IN
India
Application number
IN202321021121A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to IN202321021121A priority Critical patent/IN202321021121A/en
Priority to TW113110870A priority patent/TW202444740A/zh
Priority to CN202480028977.6A priority patent/CN121038809A/zh
Priority to AU2024249503A priority patent/AU2024249503A1/en
Priority to PCT/IN2024/050300 priority patent/WO2024201502A1/en
Priority to KR1020257035689A priority patent/KR20250166279A/ko
Priority to ARP240100707A priority patent/AR132199A1/es
Publication of IN202321021121A publication Critical patent/IN202321021121A/en
Priority to MX2025011286A priority patent/MX2025011286A/es
Priority to IL323559A priority patent/IL323559A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN202321021121A 2023-03-24 2023-03-24 IN202321021121A (enExample)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN202321021121A IN202321021121A (enExample) 2023-03-24 2023-03-24
TW113110870A TW202444740A (zh) 2023-03-24 2024-03-22 基於腦膜炎球菌蛋白的疫苗製劑及其製造方法
CN202480028977.6A CN121038809A (zh) 2023-03-24 2024-03-22 基于脑膜炎球菌蛋白的疫苗制剂以及用于制造其的方法
AU2024249503A AU2024249503A1 (en) 2023-03-24 2024-03-22 Meningococcal protein based vaccine formulations and methods for manufacturing thereof
PCT/IN2024/050300 WO2024201502A1 (en) 2023-03-24 2024-03-22 Meningococcal protein based vaccine formulations and methods for manufacturing thereof
KR1020257035689A KR20250166279A (ko) 2023-03-24 2024-03-22 수막구균 단백질 기반의 백신 제형 및 이의 제조 방법
ARP240100707A AR132199A1 (es) 2023-03-24 2024-03-25 Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación
MX2025011286A MX2025011286A (es) 2023-03-24 2025-09-24 Formulaciones vacunales basadas en proteinas meningococicas y metodos para su fabricacion
IL323559A IL323559A (en) 2023-03-24 2025-09-25 Meningococcal protein-based vaccines and methods for their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202321021121A IN202321021121A (enExample) 2023-03-24 2023-03-24

Publications (1)

Publication Number Publication Date
IN202321021121A true IN202321021121A (enExample) 2024-04-19

Family

ID=92903953

Family Applications (1)

Application Number Title Priority Date Filing Date
IN202321021121A IN202321021121A (enExample) 2023-03-24 2023-03-24

Country Status (9)

Country Link
KR (1) KR20250166279A (enExample)
CN (1) CN121038809A (enExample)
AR (1) AR132199A1 (enExample)
AU (1) AU2024249503A1 (enExample)
IL (1) IL323559A (enExample)
IN (1) IN202321021121A (enExample)
MX (1) MX2025011286A (enExample)
TW (1) TW202444740A (enExample)
WO (1) WO2024201502A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004275A2 (pt) * 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
CN105378074A (zh) * 2013-03-15 2016-03-02 费城儿童医院 在无血清悬浮细胞培养系统中生产重组慢病毒载体的可扩大的制造方法
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110804102B (zh) * 2019-11-08 2021-07-20 苏州微超生物科技有限公司 B群脑膜炎球菌疫苗及其制备方法与应用

Also Published As

Publication number Publication date
CN121038809A (zh) 2025-11-28
WO2024201502A1 (en) 2024-10-03
TW202444740A (zh) 2024-11-16
MX2025011286A (es) 2025-11-03
AR132199A1 (es) 2025-06-04
IL323559A (en) 2025-11-01
AU2024249503A1 (en) 2025-10-16
KR20250166279A (ko) 2025-11-27

Similar Documents

Publication Publication Date Title
IN202321021121A (enExample)
CN307049932S (enExample)
CN307049655S (enExample)
CN307050507S (enExample)
CN307050426S (enExample)
CN307049685S (enExample)
CN307049553S (enExample)
CN307049216S (enExample)
CN307048434S (enExample)
CN307048382S (enExample)
CN307048358S (enExample)
CN307048048S (enExample)
CN307047710S (enExample)
BY13147U (enExample)
CN307046569S (enExample)
CN307046070S (enExample)
CN307045698S (enExample)
CN307045388S (enExample)
CN307045138S (enExample)
CN307044306S (enExample)
CN307044274S (enExample)
BY13168U (enExample)
BY13167U (enExample)
BY13166U (enExample)
BY13165U (enExample)